COVID-19 USA Daily Numbers, page-354

Hi Eyeswideopen,

Join this dot: (mesoblast's announcement on December 17)
"The DSMB reported that there were no safety concerns and noted that the trial is not likely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment"

In other words, its unlikely to meet its objective.

with this dot: (my previous post)
'The term 'futility' is used to refer to the inability of a clinical trial to achieve its objective'

Clearly the objective of the trial was to meet a 30-day mortality endpoint but the DSMB have indicated that the trial was unlikely to meet that objective.

Where's the ambiguity?

I also don't like the fact that the trial is being wound up due to 'futility' but it doesn't change the fact.